A phase 1 clinical trial has shown that personalized neoantigen vaccines, given alongside PD-1 blockade, are feasible in patients with high-grade serous ovarian cancer and can trigger tumor-specific immune responses in many of them. The findings, published in Nature Medicine, also point to mechanisms of resistance tied to antigen presentation that were detected through cell-free DNA analysis.
The trial focused on high-grade serous ovarian cancer, an aggressive form of the disease that is often diagnosed at an advanced stage and has limited treatment options after standard therapies fail. Personalized neoantigen vaccines are designed around mutations unique to a patient's tumor, training the immune system to recognize and attack cancer cells that carry those mutations. Combining the vaccines with PD-1 blockade, a type of immunotherapy that releases brakes on immune cells, aims to amplify that response.
According to the study, the combination was feasible and led to tumor-specific immune responses in many patients. That means the immune systems of those participants mounted a targeted attack against the neoantigens present in their tumors. The trial was designed primarily to assess safety and feasibility, not to prove that the treatment extends survival, so the immune responses observed are an early but important signal that the approach can work as intended.
The researchers also identified putative mechanisms of resistance related to antigen presentation. Antigen presentation is the process by which cells display fragments of proteins on their surface so immune cells can recognize them. If a tumor loses or alters this machinery, immune cells may no longer see the cancer as a target, allowing the disease to evade the vaccine-induced response. The study detected these resistance-related changes through cell-free DNA analysis, a less invasive method that examines tumor DNA circulating in the blood.
That finding matters because it suggests a way to monitor how tumors adapt to personalized vaccines without repeated biopsies. Cell-free DNA analysis could help clinicians track whether a tumor is losing the antigen-presentation features that the immune system depends on, potentially guiding decisions about when to adjust treatment. The trial's authors describe the resistance mechanisms as putative, meaning they are proposed explanations based on the data rather than confirmed causes.
Ovarian cancer remains a difficult disease to treat, and immunotherapy has produced mixed results in this tumor type compared with others such as melanoma or lung cancer. The phase 1 results do not establish efficacy, and larger randomized trials would be needed to determine whether the immune responses translate into clinical benefit such as tumor shrinkage or longer survival. The study's contribution is showing that the personalized vaccine-plus-PD-1 approach can be delivered and can generate the intended immune activity in a meaningful share of patients.
The trial also adds to a broader effort to make cancer vaccines truly individualized. By targeting neoantigens, which arise from mutations specific to each patient's tumor, researchers hope to create treatments that are less likely to be ignored by the immune system than vaccines aimed at shared tumor proteins. The identification of antigen-presentation resistance through a blood-based test suggests that future trials could use cell-free DNA to select patients, monitor responses, or catch resistance early.
For now, the results support further study of personalized neoantigen vaccines in ovarian cancer. The combination was feasible, immune responses were seen in many patients, and a potential route of resistance was detectable in blood. Those three findings together provide a foundation for the next stage of research, even as the limitations of a phase 1 trial remain clear.
26
